消耗品:被忽视的具有抗癌特性的药物
Anagha J Deshpande1, Javier Munoz2, Razelle Kurzrock3,4,5
1Department of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA. Deshpaa3@ccf.org.
Current oncology reports
|November 1, 2025
概括
药物重新定位从现有药物中识别出新的癌症治疗方法. 经批准的药物,如全转录氨酸和thalidomide,在治疗白血病和多发性骨髓瘤方面显示出有效性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 癌症仍然是全球主要的死亡原因.
- 开发新型抗癌药物是一个漫长且资源密集的过程.
- 药物重新定位提供了一个有希望的策略,以加快新瘤疗法的识别.
研究的目的:
- 探索药物重新定位的潜力,以识别新的抗癌剂.
- 为了突出现有的药物重新用于癌症治疗.
- 讨论药物重新定位在瘤学的未来影响.
主要方法:
- 关于瘤学中药物重新定位的现有文献的综述.
- 识别FDA批准的药物与重新定位的抗癌指示.
- 对支持重新定位药物的疗效的临床前和临床数据的分析.
主要成果:
- 全转网红酸,最初用于光衰老,有效治疗急性肌肉细胞白血病 (APL).
- 和thalidomide,有不同的历史,分别被批准用于APL和多发性骨髓瘤.
- 抗生素 (阿莫西西林,克拉里思罗米辛,美特罗尼达) 显示对MALT淋巴瘤的疗效.
- 其他药物类别,如抗炎药,抗感染药,他类药和甲胺,都表现出抗癌特性.
结论:
- 药物重新定位成功产生了FDA批准的癌症疗法.
- 一系列现有的药物显示出重新定位为抗癌剂的潜力.
- 分子技术和癌症生物学方面的进步提高了针对性药物重新定位的前景.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
591
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
591


